HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $110 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating on Vir Biotechnology (NASDAQ:VIR), maintaining a $110 price target.
May 07, 2024 | 11:01 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vir Biotechnology's stock rating was reiterated as Buy by HC Wainwright & Co. with a price target of $110.
The reiteration of a Buy rating and a high price target by a reputable analyst firm like HC Wainwright & Co. typically signals strong confidence in the company's future performance. This endorsement can positively influence investor sentiment and potentially lead to an increase in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100